IMMUNOTHERAPY OF HEPATOCELLULAR CANCER IN THE REPUBLIC OF BASHKORTOSTAN

Abstract

Immunotherapy of hepatocellular carcinoma (HCC) is a promising trend in oncology. HCC takes up to 85% of all liver tumors. Sorafenib therapy is a standard treatment for HCC. This article analyzes the results of treatment of the study group who received immunotherapy with durbalumab (26,6%) and its combination with trelimumumab (26,6%). The control group included patients who received sorafenib 800 mg per day (46,6%). On the basis of on Republican Clinical Oncological Centre 15 patients with confirmed progression of hepatocellular cancer took part in the study. The main point of including patients in the study is the immunohistochemical conclusion on the presence of VEGF, PDGF and CTLA4 receptors in tumor samples. We evaluated the overall survival, progression-free survival. The average life expectancy was 4.5 months. Progression-free survival was observed in 4 patients (26,6%), 1 patient is currently actively receiving therapy.Immunotherapy allows for increased progression-free survival, but does not increase overall survival. Standard therapy with sorafenib shows the best results for metastatic HCC therapy.